Nurix Therapeutics (NRIX) EBT (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of EBT data on file, last reported at -$89.8 million in Q2 2026.

• On a quarterly basis, EBT fell 110.3% year-over-year to -$89.8 million in Q2 2026; TTM through May 2026 was -$342.4 million, a 65.83% decrease from a year earlier, with the FY2025 full-year figure at -$263.7 million, down 36.42% from the prior year.
• EBT for Q2 2026 stood at -$89.8 million, down from -$87.9 million in the prior quarter.
• Over the last five years, EBT for NRIX reached as high as -$24.3 million in Q2 2023 and fell as low as -$89.8 million in Q2 2026.
• Historically, EBT has averaged -$53.3 million across 5 years, with a median of -$45.6 million in 2022.
• Across the five-year window, EBT soared 46.53% in 2023 and plunged 110.3% in 2026, its largest moves.
• Year by year, EBT stood at -$46.7 million in 2022, then grew by 10.19% to -$42.0 million in 2023, then tumbled by 39.53% to -$58.5 million in 2024, then tumbled by 33.62% to -$78.2 million in 2025, then slipped by 14.81% to -$89.8 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$89.8 million in Q2 2026, -$87.9 million in Q1 2026, and -$78.2 million in Q4 2025.